Expert consensus on the detection and clinical application of tumor mutational burden - PubMed
4 days ago
- #Biomarker
- #TMB
- #Immunotherapy
- Tumor mutational burden (TMB) is an emerging biomarker for predicting tumor immunotherapy efficacy.
- TMB detection methods include whole-exome sequencing and targeted panel sequencing, but lack standardization.
- Variations in detection methods, thresholds, and reporting formats hinder TMB's clinical application.
- The consensus provides recommendations for TMB's definition, detection standardization, and clinical significance.
- Aims to help clinicians and lab personnel interpret TMB results accurately and improve patient care.